Vaccitech induces T cells and antibodies to treat and prevent disease

Learn More

Learn more Vaccitech induces T cells and antibodies to treat and
prevent disease
Learn more Human Papillomavirus causes nearly all cases of cervical cancer Learn more Chronic hepatitis B affects an estimated 257 million
people worldwide
Learn more SARS-CoV-2 has caused a worldwide pandemic of respiratory illness, commonly referred to as COVID-19

life at vaccitech

Our Mission

Image: NIAID

Treating and Preventing Disease

We develop T cell immunotherapeutic products and vaccines to improve global health

Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the most prestigious vaccine research centres in the world.

Oxford University breakthrough on global COVID-19 vaccine Oxford, UK - Vaccitech’s scientific founders at University of Oxford announce positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil. Phase 3...
Oxford University breakthrough on global COVID-19 vaccine
Oxford coronavirus vaccine produces strong immune response in older adults Vaccitech Ltd, a clinical-stage biopharmaceutical company developing vaccines and immunotherapies to treat and prevent infectious diseases and cancer, announces that the ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the...
Oxford coronavirus vaccine produces strong immune response in older adults
Vaccitech expands management team with hires including CMO and CFO Oxford, UK – Vaccitech Ltd, a clinical-stage biopharmaceutical company developing T cell vaccines and immunotherapies designed to treat and prevent infectious disease and cancer, today announces the appointment of three...
Vaccitech expands management team with hires including CMO and CFO
University of Oxford and Vaccitech to present at the ESMO Virtual Congress Oxford, UK – Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, today announces that results from ADVANCE, a Phase 1/2 study in...
University of Oxford and Vaccitech to present at the ESMO Virtual Congress
Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups Trial enrolling up to 30,000 adults aged 18 years or over to assess safety, efficacy and immunogenicity of AZD1222 for the prevention of COVID-19 AZD1222 supported by safety and immunogenicity across...
Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
Vaccitech receives government grant for COVID-19 vaccine research Oxford, UK - Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has received a non-dilutive Government grant to...
Vaccitech receives government grant for COVID-19 vaccine research

OUR APPROACH

Teaching the immune system to confront deadly infections

Traditional vaccine technology creates a pronounced antibody response to the infectious agent. Vaccitech’s platform is able to also induce potent and durable T cell responses from the cellular arm of the immune system.